Fundraising Fox
MitoRx Therapeutics
Harwell Oxford, GB · Founded 2021 · 6 known investors
Find your way into MitoRx Therapeutics
Sign up to see every warm intro you have to MitoRx Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MitoRx Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
Founders & leadership
MitoRx Therapeutics was founded in 2021 by Jon R., Jon Rees PhD, and Norman Law PhD.
Investors · 6
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Oxford Technology Management's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: UK Innovation & Science Seed Fund's portfolio page · funding news · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountpre-Series A roundJan 2026Source ↗
- Undisclosed amountpre-series A roundNov 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Companies House · registry record
View on Companies House ↗- Registered name
- MITORX THERAPEUTICS LIMITED
- Company number
- 13237941
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 2 Mar 2021
- Registered office
- 9400 Garsington Road, Oxford Business Park, Oxford, OX4 2HN
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology82990 — Other business support service activities n.e.c.
- Previous names
- IFFLEY BIOTECH LTD (2021–2021)
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 1 Mar 2026 · next due 15 Mar 2027
Current officers · 6
- Pennsec Limited — corporate secretary, appointed 2 Mar 2021
- Didier Shaun Philip Cowling — director, appointed 12 Nov 2025
- Glyn Owain Edwards — director, appointed 20 Feb 2022
- Mohammad Sohail Fazeli — director, appointed 17 Mar 2026
- Alexander Michael Fink — director, appointed 19 May 2022
- Jonathan David Rees — director, appointed 2 Mar 2021
Source: Companies House public register · retrieved 27 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does MitoRx Therapeutics do?
- MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
- Who founded MitoRx Therapeutics?
- MitoRx Therapeutics was founded by Jon R., Jon Rees PhD, Norman Law PhD in 2021.
- Who are MitoRx Therapeutics's investors?
- MitoRx Therapeutics's investors include Future Planet Capital, Oxford Investment Opportunity Network (OION), Oxford Technology Management, UK Innovation & Science Seed Fund, Empirical Ventures, Wren Capital.
- Where is MitoRx Therapeutics headquartered?
- MitoRx Therapeutics is headquartered in Harwell Oxford, GB.